These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10792093)

  • 1. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate.
    Krupski T; Petroni GR; Frierson HF; Theodorescu JU
    Urology; 2000 May; 55(5):743-9. PubMed ID: 10792093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.
    Grossfeld GD; Carroll PR; Lindeman N; Meng M; Groshen S; Feng AC; Hawes D; Cote RJ
    Urology; 2002 Jan; 59(1):97-102. PubMed ID: 11796289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
    Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
    J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage.
    Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
    BMC Urol; 2004 Dec; 4(1):14. PubMed ID: 15588310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    Cancer; 1997 Dec; 80(11):2109-19. PubMed ID: 9392333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.
    Silberman MA; Partin AW; Veltri RW; Epstein JI
    Cancer; 1997 Feb; 79(4):772-9. PubMed ID: 9024715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer.
    Revelos K; Petraki C; Scorilas A; Stefanakis S; Malovrouvas D; Alevizopoulos N; Kanellis G; Halapas A; Koutsilieris M
    Anticancer Res; 2007; 27(5B):3651-60. PubMed ID: 17972531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume.
    Ahlegren G; Pedersen K; Lundberg S; Aus G; Hugosson J; Abrahamsson P
    Urology; 2000 Dec; 56(6):1011-5. PubMed ID: 11113749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer . preliminary results and therapeutic implications.
    Mydlo JH; Kral JG; Volpe M; Axotis C; Macchia RJ; Pertschuk LP
    Eur Urol; 1998; 34(5):426-32. PubMed ID: 9803006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Connelly RR; Moul JW
    J Urol; 1998 Aug; 160(2):459-65. PubMed ID: 9679898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy.
    Noordzij MA; van der Kwast TH; van Steenbrugge GJ; Hop WJ; Schröder FH
    Int J Cancer; 1995 Jul; 62(3):252-8. PubMed ID: 7543077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
    Stackhouse GB; Sesterhenn IA; Bauer JJ; Mostofi FK; Connelly RR; Srivastava SK; Moul JW
    J Urol; 1999 Dec; 162(6):2040-5. PubMed ID: 10569564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
    Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
    Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
    Moul JW
    Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
    Stapleton AM; Zbell P; Kattan MW; Yang G; Wheeler TM; Scardino PT; Thompson TC
    Cancer; 1998 Jan; 82(1):168-75. PubMed ID: 9428494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.